Terug
60
Dagbereik
€ 39,56
€ 42,68
52-Weeksbereik
€ 39,56
€ 42,68
Volume
476
50D / 200D Gem.
€ 39,56
/
€ 39,56
Vorige Slotkoers
€ 39,56
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 18,7 | 0,3 |
| P/B | 3,5 | 2,9 |
| ROE % | 19,9 | 3,7 |
| Net Margin % | 9,6 | 3,8 |
| Rev Growth 5Y % | 10,4 | 10,0 |
| D/E | 1,6 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 0,00
€ 0,00 – € 0,00
|
1,3 B | 0 |
| FY2028 |
€ 3,34
€ 3,28 – € 3,39
|
1,3 B | 1 |
| FY2027 |
€ 2,56
€ 2,51 – € 2,60
|
1,3 B | 1 |
Belangrijkste Punten
Revenue grew 10,44% annually over 5 years — strong growth
Earnings grew 82,44% over the past year
ROE of 19,90% — decent returns on equity
Generating 163,14M in free cash flow
PEG of 0,24 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,83%
Groei
Revenue Growth (5Y)
10,44%
Revenue (1Y)2,61%
Earnings (1Y)82,44%
FCF Growth (3Y)-19,14%
Kwaliteit
Return on Equity
19,90%
ROIC10,27%
Net Margin9,64%
Op. Margin18,37%
Veiligheid
Debt / Equity
1,62
Current Ratio1,82
Interest Coverage3,71
Waardering
P/E Ratio
18,72
P/B Ratio3,52
EV/EBITDA13,78
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 2,61% | Revenue Growth (3Y) | 7,34% |
| Earnings Growth (1Y) | 82,44% | Earnings Growth (3Y) | -7,93% |
| Revenue Growth (5Y) | 10,44% | Earnings Growth (5Y) | 7,30% |
| Profitability | |||
| Revenue (TTM) | 1,18B | Net Income (TTM) | 113,79M |
| ROE | 19,90% | ROA | 5,47% |
| Gross Margin | 64,96% | Operating Margin | 18,37% |
| Net Margin | 9,64% | Free Cash Flow (TTM) | 163,14M |
| ROIC | 10,27% | FCF Growth (3Y) | -19,14% |
| Safety | |||
| Debt / Equity | 1,62 | Current Ratio | 1,82 |
| Interest Coverage | 3,71 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 18,72 | P/B Ratio | 3,52 |
| P/S Ratio | 1,80 | PEG Ratio | 0,24 |
| EV/EBITDA | 13,78 | Dividend Yield | 0,02% |
| Market Cap | 2,13B | Enterprise Value | 2,99B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 1,18B | 1,15B | 1,02B | 942,91M | 793,83M |
| Net Income | 113,79M | 62,37M | 134,24M | 209,58M | 85,83M |
| EPS (Diluted) | 2,11 | 1,16 | 2,49 | 3,89 | 1,59 |
| Gross Profit | 767,07M | 704,14M | 660,83M | 620,69M | 463,48M |
| Operating Income | 216,93M | 182,89M | 243,69M | 298,47M | 136,85M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 2,08B | 2,16B | 1,41B | 1,41B | 1,22B |
| Total Liabilities | 1,47B | 1,62B | 880,34M | 907,14M | 899,81M |
| Shareholders' Equity | 604,42M | 539,21M | 531,59M | 497,32M | 321,97M |
| Total Debt | 979,61M | 1,08B | 516,45M | 580,30M | 606,80M |
| Cash & Equivalents | 121,20M | 158,72M | 149,92M | 160,32M | 120,62M |
| Current Assets | 593,50M | 630,50M | 533,95M | 519,22M | 400,05M |
| Current Liabilities | 326,92M | 394,49M | 217,79M | 155,61M | 132,87M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#97 of 332
Recente Activiteit
Ingestapt
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026